CryoPort (NASDAQ:CYRX) Given New $15.00 Price Target at BTIG Research

Key Points

• BTIG Research has increased CryoPort's price target from $10.00 to $15.00, indicating a potential upside of 69.11% based on the stock's previous close, and maintains a "buy" rating.
• In the recent earnings report, CryoPort missed the consensus EPS estimate with a reported ($0.29) but exceeded revenue expectations with $45.45 million.
• CryoPort insiders, including CFO Robert Stefanovich and CEO Jerrell Shelton, have sold shares resulting in a decrease in their ownership, with insiders selling a total of 178,828 shares in the last 90 days.

CryoPort (NASDAQ:CYRX - Get Free Report) had its price target raised by equities research analysts at BTIG Research from $10.00 to $15.00 in a report issued on Thursday, MarketBeat.com reports. The brokerage currently has a "buy" rating on the stock. BTIG Research's price target would indicate a potential upside of 49.33% from the stock's previous close.

Several other research analysts have also commented on the stock. Leerink Partnrs upgraded shares of CryoPort from a "hold" rating to a "strong-buy" rating in a report on Wednesday, August 6th. KeyCorp upgraded shares of CryoPort from a "sector weight" rating to an "overweight" rating and set a $15.00 price objective for the company in a report on Wednesday, August 6th. Leerink Partners upgraded shares of CryoPort from a "market perform" rating to an "outperform" rating and set a $16.00 price target for the company in a research note on Wednesday, August 6th. Finally, Stephens initiated coverage on shares of CryoPort in a research note on Tuesday, July 22nd. They issued an "overweight" rating and a $13.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $12.56.

CryoPort Trading Up 0.8%

CYRX traded up $0.08 during trading on Thursday, hitting $10.05. 241,935 shares of the stock traded hands, compared to its average volume of 547,031. The firm has a market capitalization of $502.95 million, a P/E ratio of 7.54 and a beta of 1.62. The company has a debt-to-equity ratio of 0.39, a current ratio of 16.24 and a quick ratio of 15.47. The firm has a 50-day moving average of $8.41 and a 200 day moving average of $7.04. CryoPort has a 12-month low of $4.58 and a 12-month high of $10.46.

CryoPort (NASDAQ:CYRX - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.09). CryoPort had a net margin of 37.21% and a negative return on equity of 9.79%. The firm had revenue of $45.45 million for the quarter, compared to analysts' expectations of $41.74 million. CryoPort has set its FY 2025 guidance at EPS. Equities research analysts anticipate that CryoPort will post -0.99 EPS for the current year.

Insider Activity at CryoPort

In other news, CFO Robert Stefanovich sold 9,300 shares of CryoPort stock in a transaction that occurred on Tuesday, August 19th. The shares were sold at an average price of $8.67, for a total transaction of $80,631.00. Following the sale, the chief financial officer owned 207,213 shares in the company, valued at $1,796,536.71. This trade represents a 4.30% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Jerrell Shelton sold 16,344 shares of the business's stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $7.06, for a total transaction of $115,388.64. Following the completion of the sale, the chief executive officer owned 912,419 shares in the company, valued at $6,441,678.14. This represents a 1.76% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 109,693 shares of company stock worth $870,021. 10.10% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On CryoPort

Large investors have recently bought and sold shares of the business. Nisa Investment Advisors LLC increased its position in CryoPort by 299.9% in the second quarter. Nisa Investment Advisors LLC now owns 3,639 shares of the company's stock worth $27,000 after purchasing an additional 2,729 shares during the last quarter. Tower Research Capital LLC TRC increased its position in CryoPort by 300.1% in the second quarter. Tower Research Capital LLC TRC now owns 5,833 shares of the company's stock worth $44,000 after purchasing an additional 4,375 shares during the last quarter. Lazard Asset Management LLC bought a new stake in CryoPort in the fourth quarter worth $51,000. SBI Securities Co. Ltd. increased its position in CryoPort by 548,750.0% in the first quarter. SBI Securities Co. Ltd. now owns 10,977 shares of the company's stock worth $67,000 after purchasing an additional 10,975 shares during the last quarter. Finally, CWM LLC increased its position in CryoPort by 1,437.0% during the first quarter. CWM LLC now owns 11,328 shares of the company's stock valued at $69,000 after acquiring an additional 10,591 shares during the last quarter. Institutional investors own 92.90% of the company's stock.

About CryoPort

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.